Active not recruiting × Mesothelioma × Thoracic × Clear all
NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
NCT05238883 2025-11-21

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

Phase 1 Active not recruiting
72 enrolled
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 5 FDA
NCT06638931 2025-05-28

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Active not recruiting
28 enrolled
NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 1/2 Active not recruiting
179 enrolled
NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
71 enrolled